A new study from the Amsterdam University Medical Center has found that more than half of Dutch patients with a primary brain tumor have used cannabis at some point, with many citing relief of symptoms such as sleep issues, anxiety, and depression.
Researchers surveyed 100 adult patients visiting the neuro-oncology outpatient clinic between August and October 2023. Fifty-one percent reported lifetime cannabis use, and 14% were active users. Nineteen percent had used cannabis specifically for tumor-related reasons, including symptom relief (74%) and presumed tumor effects (42%).
CBD-dominant products were more popular than THC, with oral forms like drops favored over smoking. Among current users, 64% consumed cannabis daily. Self-reported benefits most often included improved sleep, reduced anxiety and worry, and relief from depressive symptoms. Reported side effects were generally mild, most commonly drowsiness, dry mouth, and dizziness.
The study also found that 21% of tumor-related cannabis users didn’t know whether their products contained THC or CBD, and dosage varied widely among those who did. Most patients who used cannabis for tumor-related purposes had begun using it before their cancer diagnosis, reflecting the Netherlands’ comparatively tolerant cannabis laws.
While preclinical research has hinted at potential antitumor effects, the authors caution that no strong clinical evidence exists for brain tumor patients. They note that the popularity of cannabis among this patient group underscores the need for more controlled trials, particularly on its impact on sleep, mental health, and tumor progression.
The researchers say doctors should be aware of cannabis use among neuro-oncology patients and discuss both potential benefits and risks, especially given that CBD, the preferred option for many patients, can affect liver function.
More articles from The Marijuana Herald:
